Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification

NCT04309409 is registered in ClinicalTrials.gov with University Hospital, Essen as lead sponsor.

NCT NCT04309409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04309409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification
Lead sponsor
University Hospital, Essen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 1, 2020
Completion date
January 31, 2028
Enrollment
374 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma stage ii